Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

Fig. 1

PFS of the different EOT MRD level groups, and according to IGHV mutational status. (A) PFS of the different MRD level groups at EOT in the whole population (both p < 0.0001 for low versus intermediate and low versus high levels). (B) PFS according to EOT MRD status (detectable versus undetectable) in IGHV-unmutated patients (p = 0.0206). (C) PFS according to EOT MRD status (detectable versus undetectable) in IGHV-mutated patients (p = 0.0002). EOT: end of treatment, MRD: minimal residual disease

Back to article page